Abstract #2720

Vascular Response of Hepatocellular Carcinoma to Pazopanib Measured by Dynamic Contrast-Enhanced MRI: Pharmacokinetic and Clinical Activity Correlations

Philip Stephen Murphy¹, Caleb Roberts², Brandon Whitcher³, Frank Stornanti⁴, Jennifer Gauvin⁵, Thomas Yau⁶, Pei-Jer Chen⁷, Martin Curtis⁵, Ben Suttle⁵, Thangam Arumugham⁵, Jeffrey Hodge⁵, Mohammed Dar⁵, Ronnie Poon⁶, Geoff JM Parker²

¹Oncology Clinical R&D, GlaxoSmithKline, Uxbridge, Middlesex, United Kingdom; ²Imaging Science and Biomedical Engineering, School of Cancer and Imaging Sciences, University of Manchester, Manchester, United Kingdom; ³Clinical Imaging Centre, GlaxoSmithKline, London, United Kingdom; ⁴Perceptive Informatics, Billerica, United States; ⁵Oncology Research, GlaxoSmithKline, Research Triangle Park, United States; ⁶Queen Mary Hospital, Hong Kong, China; ⁷National Taiwan University Hospital, Taipei, Taiwan

When performing dynamic contrast enhanced MRI (DCE-MRI) in the dose-ranging setting, correlating the readout to individual pharmacokinetic (PK) parameters is more informative than relating to dose alone. In a study of the VEGF receptor inhibitor pazopanib in hepatocellular carcinoma (HCC), relationships between image-based measures of vascular function, PK parameters, and clinical activity were observed.